Newland has obtained a drug registration certificate
I'm PortAI, I can summarize articles.
Newland recently obtained the "Drug Registration Certificate" issued by the National Medical Products Administration, which pertains to the drug Vildagliptin tablets, suitable for the treatment of type 2 diabetes. Vildagliptin, as a selective DPP-4 inhibitor, can rapidly inhibit DPP-4 activity, increase endogenous GLP-1 and GIP levels, thereby enhancing β-cell sensitivity to glucose, promoting insulin secretion, and lowering blood glucose levels
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments